Commercial Perspectives: Multiple Sclerosis - How to Find Opportunities in an Unremitting Market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2004-06-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The MS market is highly lucrative and competitive sector with only five marketed drugs worth $2.8billion in 2003. However, the dynamics of the market will shift from 2005 onwards with the launch of novel injectable and oral drugs, and the potential threat of generic competition. Manufacturers will need to review their strategies, and seek indications in new markets and niche patient cohorts.


Scope

  • In-depth profiles of current market-leading brands, including major events impacting each brand during 2003
  • Analysis of potential strategies to help maximize and protect revenues
  • Global sales (US, Japan, France, Germany, Italy, Spain, UK) for leading MS drugs from 1999 to 2003, with projections for future performance to 2012
  • Various lifecycle management strategies are analyzed, using case studies, and their applicability for the future is determined


    • Report Highlights
    The MS market has continued to grow, with revenues increasing by 23.4% in 2003, in a market valued at $2.8billion. Biogen-IDEC's Avonex remains market leader, although with the continued, rapid up-take of Rebif in the US, Avonex's days at the top are numbered.

    Manufacturers are seeking co-development and marketing agreements to increase there market share. Consequently, Serono's MS franchise is forecast to become a blockbuster in 2006, and remain so over the forecast period, while the launch of Antegren in 2005 will ensure growth of Biogen-IDEC's blockbuster franchise to 2012.

    Efficacy remains the primary unmet need of MS treatment. Despite numerous clinical trials, no drug has been approved for the treatment of primary progressive MS, the most aggressive form of MS. Moreover, Datamonitor does not believe any of the currently marketed drugs will gain an indication in this niche market.


    Reasons to Purchase

  • Assess leading MS drugs and identify key success factors within this sector
  • Understand key market drivers and predict the future performance of key compounds
  • Benchmark pipeline MS drugs against currently marketed products and assess their future market potential

    • Table of Contents

    Other users found this report page using the following search terms: multiple sclerosis neurodegenerative disease multiple sclerosis market avonex betaseron rebif copaxone ms uk price

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.